ABSTRACT AIMS AND OBJECTIVES: To study the distribution and frequencies of ABO and Rhesus (Rh) blood groups among confirmed cases of Covid19 infection .We also studied the relation between ABO blood group system and lymphopenia and studied the gender association in COVID19 patients. METHODES A hospital based retrospective study was conducted at Government Medical College Suryapet from1-8-2020 to 30-9-2020. A total of 200 Covid cases were included in the study who came to the hospital with the complaints of Fever, sore throat, body pains, cough, breathlessness, diarrhoea. Patients confirmed Covid infection were tested for blood grouping and RH typing by using forward blood grouping with the help of commercially available standared monoclonal antisera. CBP was processed in sysmax 5 part Haemotology analyzer. Blood group frequency was tested also assed the gender association , covid patients presents with lymphopenia the relation between the ABO blood group and lymphocyte count was determined. RESULTS: Males were more compared to the females .Middle aged group male patients were more commonly involved. Most predominant blood group was group B 79(39.5%), group O 78(39%),group A 37(18.5%), group AB 6(3%),most of them were 190 (95%)Rh positive, only 10 Rh negative (5%).To assess the Lymphopenia in our study we divided the absolute lymphocyte count into 5 groups. Group 1 cases are more 58 (29%), Group 2 91(45.5%), Group 3 30 (15%), Group 4 16(8%), Group 5 5(2.5%). CONCLUSION: Male patients with blood group B were more compared to other blood groups however more number of studies are necessary to confirm these findings in a larger sample and among individuals of different ethnicities. Keywords : ABO , BLOOD GROUPS, Rhesus(Rh) typing.
Recent surges in SARS-CoV-2 variants of concern (VOCs) call for the need to evaluate levels of vaccine- and infection- induced SARS-CoV-2 neutralizing antibodies (NAbs). CoronaVac (Sinovac Biotech, Beijing, China) is currently being used for mass vaccination in Thailand as well as other low-income countries. Three VOCs currently circulating within Thailand include the B.1.1.7 (Alpha), B.1.351 (Beta), and B.1.617.2 (Delta) strains. We assessed NAb potency against the prototypic strain containing the original spike sequence (WT) compared to that against the 3 VOCs using sera derived from a cohort of healthcare workers who received a full 2-dose regimen of CoronaVac. Sera from two other cohorts consisting of COVID-19 patients who had been hospitalized in 2020 and 2021 were evaluated for comparison. We found that, despite equally robust production of S1-RBD-binding IgG and 100% seropositivity, sera from both CoronaVac vaccinees and naturally infected individuals had significantly reduced neutralizing capacity against all 3 VOCs compared to WT. Strikingly, NAb titers against Alpha and Beta were comparable, but Delta appears to be significantly more refractory to NAbs in all groups. Our results may help inform on CoronaVac NAb-inducing capacity, which is a proxy for vaccine efficacy, in the context of the WT strain and 3 VOCs. Our results also have critical implications for public health decisionmakers who may need to maintain efficient mitigation strategies amid a potentially high risk for infection with VOCs even in those who have been previously infected.
Abstract Background: Coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with a newly discovered coronavirus (SARS-COV-2). Unfortunately, COVID-19 is not only a short-term infection but that patients (pts) recovering from SARS-CoV2 infection complain of persisting symptoms including: fatigue, diffuse myalgia and weakness, which may lead to chronic fatigue syndrome. There is currently no evidence that nutritional supplements and/or physical exercise can assist in the recovery of pts with chronic fatigue syndrome. 1-Methylnicotinamide (1-MNA) is an endogenic substance that is produced in the liver when nicotinic acid is metabolized. 1-MNA demonstrates anti-inflammatory and anti-thrombotic properties. Therefore, we investigated whether 1-MNA supplements could improve exercise tolerance and decrease fatigue among patients recovering from SARS-CoV-2. Methods: The study population was composed of pts after COVID-19, expressing subjective feelings of limited tolerance to exercise. The selected pts were randomized into two groups: GrM0 without supplementation; GrM1 with 1-MNA supplementation. At the beginning of the study (Phase 0), in both groups, a 6-minute walk test (6MWT) was carried out and fa-tigue assessment with Fatigue Severity Scale (FSS) was performed. After 1 month (Phase 1), a follow up FSS and 6MWT once more were performed in both groups. Results: A significant improvement in the mean distance covered in the 6MWT was noted among the pts in GrM1, compared to those in GrM0. We also noted that in GrM1 the 6MWT distance was significantly higher after 1 month of supplementation with 1-MNA, compared to the beginning of the study (515.18 m in Phase 0 vs 557.8m in Phase 1; p = 0.000034). In GrM1, significantly more pts improved their distance in the 6MWT (23 out of 25 pts, equal to 92%), by a mean of 47 meters, compared to GrM0 (15 of 25 pts, equal to 60%) (p = 0.0061). After one month, significantly more patients in the group without 1-MNA had severe fatigue (FSS ≥ 4) compared to the group with supplementation (GrM1 = 5 pts (20%) vs GrM0 = 14pts (56%); p = 0.008). Conclusions: 1-MNA supplementation significantly improved physical performance in a 6-minute walk test and reduced the percentage of patients with severe fatigue after COVID-19. The comprehensive action of 1-MNA, including anti-inflammatory and anticoagulant effects, as well as activation of the SIRT1 enzyme, may be beneficial for the recovery of patients with persistent symptoms of fatigue and low tolerance to exercise after COVID-19. Keywords: COVID-19, MNA, chronic fatigue syndrome, post-COVID syndrome
The adaptive immune system protects against infection via selection of specific antigen receptors on B-cells and T-cells. We studied the prevalent CD8 killer T-cell response mounted against SARS-CoV-2 Spike269-277 epitope YLQPRTFLL via the most frequent Human Leukocyte Antigen (HLA) class I worldwide, HLA A02. The widespread Spike P272L mutation has arisen in at least 14 different SARS-CoV-2 lineages to date, including in lineages identified as variants of concern. P272L was common in the B.1.177 lineage associated with establishing the second wave in Europe. The large CD8 T-cell response seen across a cohort of HLA A02+ convalescent patients, comprising of over 120 different TCRs, failed to respond to the P272L. Sizable populations (0.01%-0.2%) of total CD8 T-cells from individuals vaccinated against SARS-CoV-2 stained with HLA A*02-YLQPRTFLL multimers but failed to bind to the P272L reagent. Viral escape at prevalent T-cell epitopes restricted by high frequency HLA may be particularly problematic when vaccine immunity is focussed on a single protein such as SARS-CoV-2 Spike and provides a strong argument for inclusion of multiple viral proteins in next generation vaccines and highlights the urgent need for monitoring T-cell escape in new SARS-CoV-2 variants.
COVID-19 Vaccinations With a Sweepstakes - Condition: Covid19
Intervention: Behavioral: Philly Vax Sweepstakes
Sponsors:
University of Pennsylvania; Philadelphia Department of Public Health
Active, not recruiting
A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19 - Condition: COVID-19
Interventions: Drug: PF-07321332; Drug: Ritonavir; Drug: Placebo
Sponsor: Pfizer
Not yet recruiting
Building Resiliency and Vital Equity (BRAVE) Project: Understanding Native Americans’ Perceptions/Beliefs About COVID-19 Testing and Vaccination Study - Condition: Covid19 Virus Infection
Intervention: Behavioral: Protect Your Elders Campaign
Sponsors: North Carolina Central University; Lumbee Tribe of North Carolina; University of North Carolina at Pembroke
Recruiting
A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents - Condition: Covid19 Vaccine
Interventions: Biological: MVC-COV1901(S protein with adjuvant); Biological: MVC-COV1901(Saline)
Sponsor: Medigen Vaccine Biologics Corp.
Not yet recruiting
Study on Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) - Condition: COVID-19
Interventions: Biological: Recombinant SARS-CoV-2 Ad5 vectored vaccine; Biological: Inactive SARS-CoV-2 vaccine (Vero cell)
Sponsors: Jiangsu Province Centers for Disease Control and Prevention; CanSino Biologics Inc.
Not yet recruiting
Covid-19 Virtual Recovery Study - Condition: Covid19
Interventions: Behavioral: Strength RMT; Behavioral: Strength RMT and nasal breathing; Behavioral: Endurance RMT; Behavioral: Endurance RMT and nasal breathing; Behavioral: Low dose RMT
Sponsor: Mayo Clinic
Not yet recruiting
Efficacy of Amantadine Treatment in COVID-19 Patients - Condition: Patients With Moderate or Severe COVID-19
Intervention: Drug: Amantadine
Sponsors: Noblewell; Medical Research Agency (ABM); Leszek Giec Upper-Silesian Medical Centre of the Silesian Medical University in Katowice
Recruiting
Internet-based Multidisciplinary Rehabilitation for Longterm COVID-19 Syndrome - Condition: Long COVID-19
Intervention: Behavioral: Multidisciplinary Rehabilitation
Sponsors: Danderyd Hospital; St Göran Hospital, Stockholm
Recruiting
A Different Use of The Aerosol Box in COVID-19 Patients; Internal Jugular Vein Cannulation - Condition: COVID-19 Pneumonia
Intervention: Procedure: Internal jugular vein cannulation
Sponsor: Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Completed
Reconditioning Exercise for COVID-19 Patients Experiencing Residual sYmptoms - Condition: Covid19
Intervention: Other: Exercise Therapy
Sponsor:
Wake Forest University Health Sciences
Not yet recruiting
Lipid Emulsion Infusion and COVID-19 Patients - Condition: Covid19
Interventions: Drug: SMOFlipid; Other: 0.9% saline
Sponsor: Assiut University
Recruiting
Short Term, High Dose Vitamin D Supplementation in Moderate to Severe COVID-19 Disease - Condition: Covid19
Intervention: Drug: cholecalciferol 6 lakh IU
Sponsor:
Postgraduate Institute of Medical Education and Research
Not yet recruiting
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine - Condition: COVID-19
Interventions: Biological: Inactivated COVID-19 Vaccine; Biological: 23-valent pneumococcal polysaccharide vaccine; Biological: Inactivated Hepatitis A Vaccine
Sponsor:
Sinovac Research and Development Co., Ltd.
Not yet recruiting
Coenzyme Q10 as Treatment for Long Term COVID-19 - Conditions: Covid19; Long Term Covid19
Interventions: Drug: Coenzyme Q10; Drug: Placebo
Sponsors: Aarhus University Hospital; University of Aarhus; Pharma Nord
Recruiting
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge - Condition: COVID-19
Intervention: Device: NovoTTF-100L
Sponsor: NovoCure GmbH
Completed
SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway - SARS-CoV-2 can infect multiple organs, including lung, intestine, kidney, heart, liver, and brain. The molecular details of how the virus navigates through diverse cellular environments and establishes replication are poorly defined. Here, we generated a panel of phenotypically diverse, SARS-CoV-2-infectable human cell lines representing different body organs and performed longitudinal survey of cellular proteins and pathways broadly affected by the virus. This revealed universal inhibition of…
Clinical evaluation of a multiplex real-time RT-PCR assay for detection of SARS-CoV-2 in individual and pooled upper respiratory tract samples - The aim of this study was to identify and validate a sensitive, high-throughput, and cost-effective SARS-CoV-2 real-time RT-PCR assay to be used as a surveillance and diagnostic tool for SARS-CoV-2 in a university surveillance program. We conducted a side-by-side clinical evaluation of a newly developed SARS-CoV-2 multiplex assay (EZ-SARS-CoV-2 Real-Time RT-PCR) with the commercial TaqPath COVID-19 Combo Kit, which has an Emergency Use Authorization from the FDA. The EZ- SARS-CoV-2 RT-PCR…
Chemical design principles of next-generation antiviral surface coatings - The ongoing coronavirus disease 2019 (COVID-19) pandemic has accelerated efforts to develop high-performance antiviral surface coatings while highlighting the need to build a strong mechanistic understanding of the chemical design principles that underpin antiviral surface coatings. Herein, we critically summarize the latest efforts to develop antiviral surface coatings that exhibit virus-inactivating functions through disrupting lipid envelopes or protein capsids. Particular attention is…
Covalent Antiviral Agents - Nowadays, many viral infections have emerged and are taking a huge toll on human lives globally. Meanwhile, viral resistance to current drugs has drastically increased. Hence, there is a pressing need to design potent broad-spectrum antiviral agents to treat a variety of viral infections and overcome viral resistance. Covalent inhibitors have the potential to achieve both goals owing to their biochemical efficiency, prolonged duration of action, and the capability to inhibit shallow,…
Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate - Viral mRNA cap methyltransferases (MTases) are emerging targets for the development of broad-spectrum antiviral agents. In this work, we designed potential SARS-CoV-2 MTase Nsp14 and Nsp16 inhibitors by using bioisosteric substitution of the sulfonium and amino acid substructures of the cosubstrate S-adenosylmethionine (SAM), which serves as the methyl donor in the enzymatic reaction. The synthetically accessible target structures were prioritized using molecular docking. Testing of the…
A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma - The detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific antibodies in the serum of an individual indicates prior infection or vaccination. However, it provides limited insight into the protective nature of this immune response. Neutralizing antibodies recognizing the viral spike protein are more revealing, yet their measurement traditionally requires virus- and cell-based systems that are costly, time-consuming, inflexible, and potentially biohazardous. Here, we…
Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has caused worldwide pandemic and is responsible for millions of worldwide deaths due to -a respiratory disease known as COVID-19. In the search for a cure of COVID-19, drug repurposing is a fast and cost-effective approach to identify anti-COVID-19 drugs from existing drugs. The receptor binding domain (RBD) of the SARS-CoV-2 spike protein has been a main target for drug designs to block spike protein binding to ACE2 proteins. In this…
Reconfiguration and dedifferentiation of functional networks during cognitive control across the adult lifespan - Healthy aging is accompanied by reduced cognitive control and widespread alterations in the underlying brain networks; but the extent to which large-scale functional networks in older age show reduced specificity across different domains of cognitive control is unclear. Here we use cov-STATIS (a multi-table multivariate technique) to examine similarity of functional connectivity during different domains of cognitive control-inhibition, initiation, shifting, and working memory-across the adult…
A possible interaction between favipiravir and methotrexate: Drug-induced hepatotoxicity in a patient with osteosarcoma - INTRODUCTION: Favipiravir is an antiviral agent that is recently used for SARS-CoV2 infection. The drug-drug interactions of favipiravir especially with chemotherapeutic agents in a patient with malignancy are not well known.
Autoimmune- and complement-mediated hematologic condition recrudescence following SARS-CoV-2 vaccination - A variety of autoimmune disorders have been reported after viral illnesses and specific vaccinations. Cases of de novo immune thrombocytopenia (ITP) have been reported after SARS-CoV-2 vaccination, although its effect on preexisting ITP has not been well characterized. In addition, although COVID-19 has been associated with complement dysregulation, the effect of SARS-CoV-2 vaccination on preexisting complementopathies is poorly understood. We sought to better understand SARS-CoV-2…
Cationic Compounds with SARS-CoV-2 Antiviral Activity and their Interaction with OCT/MATE Secretory Transporters - In the wake of the COVID-19 pandemic, drug repurposing has been highlighted for rapid introduction of therapeutics. Proposed drugs with activity against SARS-CoV-2 include compounds with positive charges at physiological pH, making them potential targets for the organic cation (OC) secretory transporters of kidney and liver, i.e., the basolateral Organic Cation Transporters, OCT1 and OCT2; and the apical Multidrug And Toxin Extruders, MATE1 and MATE2-K. We selected several compounds proposed to…
COVID-19 diagnosis and testing in pediatric heart transplant recipients - Pediatric heart transplant recipients have been expected to be at higher risk of adverse events from developing COVID-19 infection. COVID-19 RNA PCR and antibody testing has been performed in our cohort of patients since March 15, 2020 and outcomes were reviewed. COVID-19 infection in our population of pediatric heart transplant recipients is common (21%), despite recommendations to avoid contact with others. Asymptomatic COVID-19 infection is common as well (55%). Despite the frequency of…
Determination of camostat and its metabolites in human plasma - preservation of samples and quantification by a validated UHPLC-MS/MS method - CONCLUSIONS: A methodology was developed that preserves camostat and GBPA in plasma samples and provides accurate and sensitive quantification of camostat, GBPA and GBA by UHPLC-MS/MS.
Accurate Bulk Quantitation of Droplet Digital Polymerase Chain Reaction - Droplet digital PCR provides superior accuracy for nucleic acid quantitation. The requirement of microfluidics to generate and analyze the emulsions, however, is a barrier to its adoption, particularly in low resource settings or clinical laboratories. Here, we report a novel method to prepare ddPCR droplets by vortexing and readout of the results by bulk analysis of recovered amplicons. We demonstrate the approach by accurately quantitating SARS-CoV-2 sequences using entirely bulk processing…
Advanced Machine Learning System combating COVID-19 virus Detection, Spread, Prevention and Medical Assistance. - - link
Differential detection kit for common SARS-CoV-2 variants in COVID-19 patients - - link
SARS-CoV-2 anti-viral therapeutic - - link
一种基于联邦学习的多用户协同训练人流统计方法及系统 - 本发明提供一种基于联邦学习的多用户协同训练人流统计方法,旨在利用联邦学习框架搭建一个新颖的人群计数模型,达到让多用户多设备同时训练的目的。各个客户端利用图像数据集对图像分类网络进行本地训练以获取本地模型;在各经过至少一次本地训练后,中心服务器从客户端获取本地模型的权值及附加层参数并进行聚合处理;中心服务器利用聚合处理后的权值及附加层参数更新全局模型,并将聚合处理后的权值参数及附加层参数返回给各个客户端;各个客户端利用中心服务器返回的权值以及ground truth值进行贝叶斯估计,计算loss值,并利用返回的权值参数及附加层参数更新本地模型;重复执行直至所有客户端的loss值均收敛,则完成人流统计全局模型和本地模型的训练。 - link
A POLYHERBAL ALCOHOL FREE FORMULATION FOR ORAL CAVITY - The present invention generally relates to a herbal composition. Specifically, the present invention relates to a polyherbal alcohol free composition comprising of Glycyrrhiza glabra root extract, Ocimum sanctum leaf extract, Elettaria cardamomum fruit extract, Mentha spicata (Spearmint) oil and Tween 80 and method of preparation thereof. The polyherbal alcohol free composition of the present invention possesses excellent antimicrobial properties and useful for oral cavity. - link
新型冠状病毒B.1.351南非突变株RBD的基因及其应用 - 本发明属于生物技术领域,具体涉及新型冠状病毒B.1.351南非突变株RBD的基因及其应用。本发明的新型冠状病毒B.1.351南非突变株RBD的基因,其核苷酸序列如SEQIDNO.1或SEQIDNO.6所示。本发明通过优化野生型新型冠状病毒南非B.1.351南非突变株RBD的基因序列,并结合筛选确定了相对最佳序列,优化后序列产生的克隆表达效率比野生型新型冠状病毒B.1.351南非突变株RBD序列表达效率大幅提高,从而,本发明的新型冠状病毒B.1.351南非突变株RBD的基因可以用于制备新型冠状病毒疫苗。 - link
检测新型冠状病毒中和抗体的试剂盒及其应用 - 本发明涉及生物技术领域,具体而言,提供了一种检测新型冠状病毒中和抗体的试剂盒及其应用。本发明提供的检测新型冠状病毒中和抗体试剂盒,具体包括(a)或(b)两种方案:(a)示踪物标记的RBD三聚体抗原,包被在固体支持物上的ACE2,以及,含有0.2‑10mg/mL十二烷基二甲基甜菜碱的工作液;(b)示踪物标记的ACE2,包被在固体支持物上的RBD三聚体抗原,以及,含有0.2‑10mg/mL十二烷基二甲基甜菜碱的工作液;其中,RBD三聚体抗原利用二硫键将刺突蛋白的RBD与S2亚基完全交联得到。十二烷基二甲基甜菜碱会显著提高RBD三聚体抗原与新冠中和性抗体结合速度,提升阳性样本平均发光强度,缩短检测时间。 - link
一种检测SARS-CoV-2的引物组合物及其应用 - 本发明涉及一种检测SARS‑CoV‑2的引物组合物及其应用。所述引物组合物包括SEQ ID NO:1~SEQ ID NO:12所示的核酸序列。本发明利用所述引物组合物进行逆转录巢式PCR,并结合Sanger测序,能够快速、准确地获取SARS‑CoV‑2基因信息,从而能够实现快速检测SARS‑CoV‑2以及判断SARS‑CoV‑2突变株,且具备良好的准确性、灵敏度、特异性以及重复性。 - link
基于多重荧光定量PCR技术的新冠病毒突变序列检测技术及其应用 - 本发明提供一种基于多重荧光定量PCR技术的新冠病毒突变类型检测技术及其应用。本发明主要基于荧光定量PCR技术针对目前S基因重要突变类型,如序列位置23403,序列变化A>G、序列位置23063,序列变化A>T、序列位置22812‑22813,序列变化AG>GA、序列位置23012,序列变化G>A进行单管或多管多重检测。其试剂盒可以很好的鉴别目前流行的D614G、N501Y、K417N、E484K重要突变株且特异性好,对新冠病毒的突变监测具有十分积极的意义。 - link
基于荧光定量PCR技术的新冠病毒新型核酸突变检测技术及其应用 - 本发明提供一种基于荧光定量PCR技术的新冠病毒新型核酸突变检测技术及其应用。本发明主要基于荧光定量PCR技术针对目前S基因新突变‑双重变异(E484Q和L452R突变)进行检测。本发明提供的试剂盒可以很好的鉴别E484Q和L452R突变,对新冠病毒的新突变快速监测具有十分积极的意义。 - link